The antiseptic Miramistin: a review of its comparative in vitro and clinical activity

Ali Osmanov, Zara Farooq, Malcolm Richardson, D W Denning

Research output: Contribution to journalArticlepeer-review


Miramistin is a topical antiseptic with broad antimicrobial action, including activity against biofilms, and a clinical profile showing good tolerability. Miramistin was developed within a framework of the Soviet Union Cold War Space Program. It is available for clinical use in several prior Soviet bloc countries, but barely known outside of these countries and there is almost no mention of miramistin in the English literature. However, considering emerging antimicrobial resistance, the significant potential of miramistin justifies its re-evaluation for use in other geographical areas and conditions. The review consists of two parts: 1) a review of the existing literature on miramistin in English, Russian, and Ukrainian languages; 2) a summary of most commonly used antiseptics as comparators of miramistin. The oral LD50 was 1200 mg/kg, 1000 mg/kg and 100 g/L in rats, mice and fish respectively. Based on the results of the review, we suggest possible applications of miramistin and potential benefits over currently used agents. Miramistin offers a novel, low toxicity antiseptic with many potential clinical uses that need better study which could address some of the negative impact of antimicrobial, antiseptic and disinfectant resistance.
Original languageEnglish
JournalF E M S Microbiology Reviews
Publication statusAccepted/In press - 5 May 2020


  • miramistin
  • toxicity
  • Candida
  • MRSA
  • antimicrobial resistance


Dive into the research topics of 'The antiseptic Miramistin: a review of its comparative in vitro and clinical activity'. Together they form a unique fingerprint.

Cite this